GSA Capital Partners’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $67K | Buy |
46,969
+16,453
| +54% | +$23.5K | ﹤0.01% | 1642 |
|
|
2025
Q1 | $47K | Buy |
+30,516
| New | +$47K | ﹤0.01% | 1550 |
|
|
2024
Q4 | – | Sell |
-255,032
| Closed | -$293K | – | 1562 |
|
|
2024
Q3 | $293K | Sell |
255,032
-81,645
| -24% | -$93.8K | 0.02% | 1225 |
|
|
2024
Q2 | $370K | Sell |
336,677
-342,460
| -50% | -$376K | 0.03% | 1151 |
|
|
2024
Q1 | $842K | Sell |
679,137
-908,858
| -57% | -$1.13M | 0.07% | 554 |
|
|
2023
Q4 | $1.67M | Buy |
1,587,995
+1,550,026
| +4,082% | +$1.63M | 0.14% | 182 |
|
|
2023
Q3 | $260K | Sell |
37,969
-45,491
| -55% | -$312K | 0.02% | 1153 |
|
|
2023
Q2 | $865K | Buy |
83,460
+51,102
| +158% | +$530K | 0.09% | 397 |
|
|
2023
Q1 | $262K | Buy |
+32,358
| New | +$262K | 0.03% | 1107 |
|